C07K 16/2827
Against b7 molecules
Official title: {against B7 molecules, e.g. CD80, CD86}
C07K16/2827 (Against b7 molecules) appears on 1,730 US grants and 4,308 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,730
- Published applications
- 4,308
- Assignees
- 1,396
- Inventors
- 8,098
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 10 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 4 |
| 2002 | 1 | 20 |
| 2003 | 3 | 13 |
| 2004 | 8 | 7 |
| 2005 | 10 | 16 |
| 2006 | 9 | 18 |
| 2007 | 4 | 14 |
| 2008 | 11 | 18 |
| 2009 | 17 | 28 |
| 2010 | 11 | 22 |
| 2011 | 9 | 17 |
| 2012 | 10 | 25 |
| 2013 | 12 | 33 |
| 2014 | 19 | 46 |
| 2015 | 24 | 62 |
| 2016 | 32 | 109 |
| 2017 | 39 | 141 |
| 2018 | 62 | 208 |
| 2019 | 100 | 320 |
| 2020 | 138 | 425 |
| 2021 | 158 | 526 |
| 2022 | 233 | 459 |
| 2023 | 217 | 477 |
| 2024 | 220 | 526 |
| 2025 | 226 | 438 |
| 2026 | 132 | 336 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Methods of cancer treatment with PD-L1 targeted interferon therapeutic agents6 Oct 2026US 12,753,233 B2Orionis Biosciences BV
- Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof6 Oct 2026US 12,753,234 B2Purdue Research Foundation
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Pharmaceutical kits and uses thereof for treating colorectal cancer29 Sep 2026US 12,746,226 B2Anbogen Therapeutics, Inc
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
- Bispecific fusion proteins with immunosuppressive activity8 Oct 2026US 2026/0308227 A1
- Methods and compositions for treating cancer8 Oct 2026US 2026/0308241 A1Chugai Seiyaku Kabushiki Kaisha
- Immunotherapeutic proteins8 Oct 2026US 2026/0308271 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Combination therapy of polio virus receptor inhibitors and fucose8 Oct 2026US 2026/0309713 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005